Haisco Pharmaceutical (SHE:002653) received clinical trial approval from China's National Medical Products Administration for its self-developed HSK60002 tablets, indicated for inflammatory diseases, according to a Thursday filing with the Shenzhen bourse.
Shares rose 1% during morning trading on Thursday.